JINARC 30 mg, tablet 7 tablets
Active ingredients: Tolvaptan
Commercialized according to BDPMDispensing in France: Prescription only
Tablet7 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- JINARC 30 mg, comprimé
- Pharmaceutical form
- comprimé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC-Aluminium de 7 comprimé(s)
- Marketing authorisation holder
- OTSUKA PHARMACEUTICAL NETHERLANDS (PAYS BAS)
- Reimbursement according to BDPM
- 30%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>Polykystose rénale autosomique dominante authentifiée chez les patients adultes et progresseurs (c'est-à-dire avec un certain nombre de critères concernant la fonction rénale), le but recherché étant de ralentir la progression du développement des kystes et de l'insuffisance rénale ; JOURNAL OFFICIEL ; 14/01/20
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 Jul 2016
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
66056341CIP73001345CIP133400930013458Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TOLVAPTANcomprimé | 30 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The published catalog does not list other packages of similar medicines.